P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Bibliographic Details
Main Authors:	Huilai Zhang, Ying Cheng, Hai-Yan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Zhiyu Liang, Jiaoyan Lyu, Yiqian Fang, Aileen Cohen, Keshu Zhou
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971440.18283.04

Similar Items

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Xiyuan Zhang, et al.
Published: (2023-08-01)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
by: Keshu Zhou, et al.
Published: (2021-10-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Xianggui Yuan, et al.
Published: (2022-11-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
by: Jorge J Castillo, et al.
Published: (2023-02-01)

Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
by: Yuqin Song, et al.
Published: (2023-09-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2011-12-01)

A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia
by: Bingjie Ding, et al.
Published: (2025-02-01)

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
by: Wei Xu, et al.
Published: (2020-05-01)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
by: Antonio Salar Silvestre, et al.
Published: (2023-08-01)

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
by: Zhiguang Lin, et al.
Published: (2023-08-01)

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors
by: Nkolika Nwankwo, et al.
Published: (2024-01-01)

Lenalidomide: An Alternative Treatment for Refractory Behçet’s Disease and Relapsing Polychondritis
by: Sofia Gomes Brazao, et al.
Published: (2019-05-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
by: Meletios A. Dimopoulos, et al.
Published: (2018-12-01)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
by: Judith Trotman, et al.
Published: (2023-08-01)

P1136: INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING
by: V. Ramos De Ascanio, et al.
Published: (2022-06-01)

Norman rule in Cumbria, 1092-1136
by: Sharpe, R
Published: (2006)

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS
by: H. Quach, et al.
Published: (2022-06-01)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01)

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
by: Chaitra Ujjani, et al.
Published: (2018-04-01)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
by: Ajay Major, et al.
Published: (2021-07-01)

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
by: Jonathan Wong, et al.
Published: (2018-12-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
by: Yuqin Song, et al.
Published: (2024-01-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
by: Giulio Cassanello, et al.
Published: (2024-09-01)

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
by: Todd A. Fehniger, et al.
Published: (2023-09-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma
by: Kolonic Slobodanka, et al.
Published: (2010-05-01)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
by: S. Opat, et al.
Published: (2022-06-01)

P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
by: Alan Skarbnik, et al.
Published: (2023-08-01)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
by: Yuchen Zhang, et al.
Published: (2022-11-01)